{"title": "SAMe: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews", "author": null, "url": "https://www.webmd.com/vitamins/ai/ingredientmono-786/same", "hostname": "webmd.com", "description": "Learn more about SAMe uses, effectiveness, possible side effects, interactions, dosage, user ratings and products that contain SAMe.", "sitename": "webmd.com", "date": "2005-01-01", "cleaned_text": "Overview [homocysteine](https://www.webmd.com/heart-disease/homocysteine-risk)and folate. It can also be made in a lab and taken in [supplements](https://www.webmd.com/men/video/lamm-supplements-diet). SAMe is involved in the formation, activation, and breakdown of other chemicals in the body, including hormones, proteins, and certain drugs. The body uses it to make certain chemicals that play a role in pain, [depression](https://www.webmd.com/depression/understanding-depression-basics), [liver disease](https://www.webmd.com/hepatitis/liver-and-hepatic-diseases), and other conditions. People most commonly take SAMe for depression and [osteoarthritis](https://www.webmd.com/osteoarthritis/osteoarthritis-basics). It is also used for anxiety, liver disease, [fibromyalgia](https://www.webmd.com/fibromyalgia/understanding-fibromyalgia-basics), schizophrenia, and many other conditions, but there is no good scientific evidence to support these uses. SAMe has been available as a [dietary supplement](https://www.webmd.com/vitamins-and-supplements/supplement-faq)in the US since 1999, but it has been used as a prescription drug in Italy, Spain, and Germany for many decades. Uses & Effectiveness ? Likely Effective for - Osteoarthritis. Taking SAMe by [mouth](https://www.webmd.com/oral-health/ss/slideshow-mouth-problems)seems to work about as well as [ibuprofen](https://www.webmd.com/drugs/2/drug-5166/ibuprofen+oral/details)and other similar drugs for reducing [symptoms of osteoarthritis](https://www.webmd.com/osteoarthritis/osteoarthritis-symptoms). But most people need to take SAMe for about a month before they feel better. Possibly Effective for - Reduced or blocked flow of bile from the [liver](https://www.webmd.com/digestive-disorders/picture-of-the-liver)(cholestasis). Taking SAMe by [mouth](https://www.webmd.com/oral-health/rm-quiz-mouth-myths)or by IV is about as effective as taking the prescription drug called ursodeoxycholic acid. IV products can only be given by a [healthcare](https://www.webmd.com/health-insurance/rm-quiz-insurance-basics)provider. - Depression. Taking SAMe by mouth might reduce symptoms of [major depression](https://www.webmd.com/depression/major-depression)in some people. It might be helpful for people who don't have a good response to prescription [antidepressants](https://www.webmd.com/depression/depression-medications-antidepressants). Sometimes it's helpful when used together with prescription antidepressants. Side Effects [diarrhea](https://www.webmd.com/digestive-disorders/digestive-diseases-diarrhea), [constipation](https://www.webmd.com/digestive-disorders/digestive-diseases-constipation), [dry mouth](https://www.webmd.com/oral-health/dental-health-dry-mouth), [headache](https://www.webmd.com/migraines-headaches/migraines-headaches-basics), and nervousness, especially at Precautions and Warnings [diarrhea](https://www.webmd.com/digestive-disorders/digestive-diseases-diarrhea), [constipation](https://www.webmd.com/digestive-disorders/digestive-diseases-constipation), [dry mouth](https://www.webmd.com/oral-health/dental-health-dry-mouth), [headache](https://www.webmd.com/migraines-headaches/migraines-headaches-basics), and nervousness, especially at higher doses. Pregnancy and [breast](https://www.webmd.com/women/picture-of-the-breasts)-feeding: There isn't enough reliable information to know if SAMe is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use. [Bipolar disorder](https://www.webmd.com/bipolar-disorder/understanding-bipolar-disorder-basics): SAMe can cause people with bipolar disorder to enter a manic state. If you have bipolar disorder, don't use SAMe. Inherited disorder called Lesch-Nyhan syndrome: SAMe might make symptoms of Lesch-Nyhan syndrome worse. Parkinson disease: There is some concern that SAMe might make symptoms of Parkinson disease worse. Surgery: SAMe might affect the [central nervous system](https://www.webmd.com/brain/what-is-nervous-system). This could interfere with surgery. Stop taking SAMe at least 2 weeks before a scheduled surgery. Interactions ? Levodopa interacts with SAMe Levodopa is used for Parkinson disease. SAMe can change levodopa in the body and decrease its effects. Taking SAMe along with levodopa might make Parkinson disease symptoms worse. Do not take SAMe if you are taking levodopa. Serotonergic drugs interacts with SAMe SAMe might increase a brain chemical called serotonin. Some medications also have this effect. Taking SAMe along with these medications might increase serotonin too much. This might cause serious side effects including heart problems, seizures, and vomiting. Moderate Interaction Be cautious with this combination Dosing [healthcare](https://www.webmd.com/health-insurance/video/what-is-the-aca)provider to find out what dose might be best for a specific condition. [View References] Adachi Y, Nanno T, Kanbe A, and The effects of S-adenosylmethionine on intrahepatic cholestasis. Jpn Arch Intern Med 1986;33(6):185-192. Agency for Healthcare Research and Quality. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evidence Report/Technology Assessment: Number 64 2002; Agnoli, A., and Cerbo, R. Effect of s-adenosyl-l-methionine (SAMe) upon depressive symptoms. J Psychiatr.Res 1976;13(1):43-54. View abstract. Agricola R, Dalla Verde G, Urani R, and et al. S-adenosyl-L-methionine in the treatment of major depression complicating chronic alcoholism. Curr Ther Res 1994;55(1):83-92. Altomare E, Vendemiale G C C. Increased bioavailability of sulfurated compounds after s-adeno- sylmethionine (SAMe) administration to alcoholics. Biomedical and social aspects of alcohol and alcoholism. 1988;353-356. Andreoli V, Campedelli A, and Maffei F. La Q. M. and Day, C. P. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J.Hepatol. 2012;57(5):1097-1109. View abstract. Bacci, Ballerini F., Lopez, Anguera A., Alcaraz, P., and Hernandez, Bell KM, Potkin SG, Carreon L, and et al. Oral S-adenosylmethionine in the treatment of depression: a double blind, randomized comparison with desipramine. Study Report BioResearch File 1990; Belmont AD, Henkel RD, and Ancira FU. [Parenteral SAMe as compared to a placebo in the treatment of alcoholic liver disease]. An Med Interna 1996;13(1):9-15. Bilton D, Schofield D, Mei G, and et al. Placebo-controlled trials of antioxidant therapy including S-adenosylmethionine in patients with recurrent nongallstone pancreatitis. Drug Invest 1994;8(1):10-20. Bombardieri G, Milani A, Bernardi L, and et al. Effects of S-adenosyl-L-methionine (SAMe) in the treatment of Gilbert's syndrome. Curr Ther Res 1985;37(3):580-585. Bonfirraro (SAMe)-induced amelioration of intrahepatic cholestasis of pregnancy. Results of an open study. Drug Invest 1990;2(2):125-128. Bortolini M, Catalino F, Scarponi S, and et al. Efficacy and safety of intravenous (IV) S-adenosylmethionine (SAMe) in the management pregnancy [abstract]. Hepatology 1991;14:250A. Bottiglieri, T. Hyland, K. S-adenosylmethionine neurological disorders: a review. Scand Suppl 1994;154:19-26. View abstract. T., Godfrey, P., Flynn, T., Carney, M. W., Toone, B. K., and Reynolds, E. H. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 1990;53(12):1096-1098. View abstract. Bradley, J., Flusser, D., Brandt, K., and et al. S-adenosyl methionine (SAMe) in the treatment of osteoarthritis (OA) of the knee. Arthritis Rheum 1991;34(suppl 9):S86. con placebo [Effects of SAMe on liver function tests in patients with chronic liver disease. A comparison with placebo]. Gazz Med Ital 1982;141(10):557-562. Burrows, R. F., Clavisi, O., Burrows, E. for treating cholestasis in pregnancy (Cochrane Review). Cochrane Database.Syst Rev 2001;4:CD000493. View abstract. Cacciatore L, Varriale A, Cozzolino G, and et al. S-adenosylmethionine (SAMe) in the treatment of pruritus in chronic liver disease. Acta Therapeutica 1989;15:363-371. Calandra, C., Roxas, M., and Rapisarda, V. [Antidepressant action of SAM in comparison to chlorimipramine. Hypotheses to interpret the mechanism of action]. Minerva Psichiatr. 1979;20(2):147-152. View abstract. Cantoni, C. J. The Nature of the Active Methyl Donor Formed Enzymatically from L-Methionine and Adenosinetriphosphate. J Am Chem Soc 1952;74(11):2942-3. Capretto C, Cremona C, and Canaparo L. A double-blind study of (SAMe) v. in gonarthrosis, coxarthrosis and spondylarthrosis. J 1985;22(1):15-24. Carney, M. W., Edeh, J., Bottiglieri, T., Reynolds, E. M., and Toone, B. K. Affective illness and S-adenosyl methionine: a preliminary report. Clin Neuropharmacol. 1986;9(4):379-385. View abstract. Carney, M. W., Martin, R., Bottiglieri, T., Reynolds, E. H., Nissenbaum, H., Toone, B. K., and Sheffield, B. N. Switch mechanism in affective illness and S-adenosylmethionine. Lancet 4-9-1983;1(8328):820-821. View abstract. Caroli A. Studio in doppio SAMe (capsule) - Aspirina nell'osteoartrosi. G Clin Med Carpenter, D. J. St. John's wort and S-adenosyl methionine as \"natural\" alternatives to conventional antidepressants in the era of the suicidality boxed warning: what is the evidence for clinically relevant benefit? Altern.Med.Rev. 2011;16(1):17-39. View abstract. Carrieri PB, Indaco A, Gentile S, and et al. S-adenosylmethionine treatment of depressioin in patients with Parkinson's disease: Caruso I, Fumagalli M, Boccassini L, and et al. Treatment of depression in rheumatoid arthritic patients. A comparison of S-adenosylmethionine (Samyr*) and placebo in a double-blind study. Clin 1987;24(4):305-310. Caruso, I., Fumagalli, L., Puttini, P. S., Ciniselli, G., and Cavallari, G. Antidepressant activity of S-adenosylmethionine. Lancet 4-21-1984;1(8382):904. View abstract. Catalino F, Scarponi S, Cesa F, and et al. Efficacy and safety of intravenous S-adenosyl-L-methionine therapy in the management of intrahepatic cholestasis of pregnancy. Drug Invest 1992;4(Suppl 4):78-82. Cergnul I, Jones K, Ernst D, and et al. S-adenosylmethionine (SAM-e) in the treatment of depressive disorders in HIV-positive individuals: interim results [poster]. Poster presentation at the13th update conference 2001; Cerutti PG, Savoini G, D'avola G, and et al. Evaluation of the efficacy of s-adenosylmethionine in the treatment of depressive disorders: a controlled clinical trial against minaprine. 1989;19(10):591-595. Cerutti R, Sichel M, and et al. Psychological distress during puerperium: a novel therapeutic approach using S-adenosylmethionine. Curr Ther Res 1993;53(6):707-716. Chinchilla, M. A., Vega F., and Alvarez, C. Suicide attempt by self-burning associated with ingestion of S-adenosylmethionine: a review of the literature and case report. J.Nerv.Ment.Dis. 2012;200(1):99-101. View abstract. Cibin M, Gentile N, Ferri M, and et al. S-adenosylmethionine (SAMe) is effective in reducing ethanol abuse in an outpatient program for alcoholics. In: Kuriyama K, Takada A, and Ishii H. Biomedical and social aspects of alcohol and alcoholism. Kyoto, Japan: Elsevier Science Publishers BV (Biomedical Division);1988. Coltorti, M., Bortolini, M., and Di Padova, C. A review of the studies on the clinical use of S-adenosylmethionine (SAMe) for the symptomatic treatment of intrahepatic cholestasis. M, Pliego M, and et al. Effect of S-adenosylmethionine treatment on methionine intolerance in and et al. Results of treatment with S-adenosyl-L-methionine in patients with major depression and internal illnesses. Curr Ther Res 1994;55(6):666-674. Cucinotta, D., Mancini, M., Ceccato, S., and Castino, E. [Controlled clinical study of SAMe (S-adenosylmethionine) administered orally in degenerative osteoarticular pathology]. G.Clin Med 1980;61(7):553-566. View abstract. De Leo D. S-adenosyl-L-methionine (SAMe) in clinical practice: preliminary report on 75 minor depressives. Curr Ther Res 1985;37(4):658-661. De Leo D. S-adenosylmethionine a double-blind trial versus placebo. Curr Ther Res 1987;41(6):865-870. De Vanna and S-adenosyl-L-methionine in depression. Curr Ther Res 1992;52(3):478-485. De, Silva, V, El-Metwally, A., Ernst, E., Lewith, G., and Macfarlane, G. J. Evidence for the efficacy of complementary and alternative medicines in the management of fibromyalgia: a systematic review. Rheumatology.(Oxford) 2010;49(6):1063-1068. View abstract. Del Vecchio M, Iorio G, Cocorullo M, and et al. Has SAMe (Ado-Met) an antidepressant effect? A 2 European multicenter controlled trials with ademetionine (SAMe) in major depression [abstract]. Psychiatry 1997;42:245S. Delle Chiaie R and Pancheri P. [Combined analysis of two controlled multicentric, double blind studies to assess efficacy and safety of Sulfo-Adenosyl-Methionine (SAMe) vs. placebo (MC1) and SAMe vs. clomipramine (MC2) in the multicentre, controlled efficacy and safety trial of oral S-adenosyl-methionine (SAMe) vs. oral imipramine in the treatment of depression. Int J Neuropsychopharmacol 2000;3(Suppl 1):S230. Di Benedetto P, Iona LG, and Zidarich V. Clinical evaluation of S-adenosyl-L-methionine versus transcutaneous electrical nerve stimulation in primary fibromyalgia. Curr Ther Res 1993;53(2):222-229. Di Palma, D., Fiore, M., et al. Prime sul trattamento delle epatiti acute con SAMe [First acquirements on the treatment of the acute hepatitis with SAMe]. G Mal Infett Parassit 1978;30(8):651-662. Di Rocco, A., Rogers, J. D., Brown, R., Werner, P., and Bottiglieri, T. S-Adenosyl-Methionine improves depression in patients with Parkinson's disease in an open-label clinical trial. Mov Disord 2000;15(6):1225-1229. View abstract. Echols, J. Naidoo, U., C. SAMe (S-adenosylmethionine). Harv.Rev.Psychiatry 2000;8(2):84-90. View abstract. Everson, G. T., Ahnen, D., Harper, P. C., and Krawitt, E. L. Benign recurrent intrahepatic cholestasis: treatment with S- Gastroenterology 1989;96(5 abstract. Fava, M., Rosenbaum, J. F., Birnbaum, R., Kelly, K., Otto, M. W., and MacLaughlin, R. The thyrotropin response to thyrotropin-releasing hormone as a predictor of response to treatment in depressed outpatients. Acta Psychiatr.Scand 1992;86(1):42-45. View abstract. Fava, M., Rosenbaum, J. F., MacLaughlin, R., Falk, W. E., Pollack, M. H., Cohen, L. S., Jones, L., and Pill, L. Neuroendocrine effects of S-adenosyl-L-methionine, a novel putative antidepressant. J Psychiatr.Res 1990;24(2):177-184. View abstract. Fazio, C., Andreoli, V., Agnoli, A., Casacchia, M., and Cerbo, R. [Therapeutic effects and mechanism of action of S-adenosyl-L-methionine (SAM) in depressive syndromes]. Minerva Med 4-30-1973;64(29):1515-1529. View abstract. Fetrow, C. W. and Avila, J. R. Efficacy of the dietary supplement S-adenosyl-L-methionine. Ann Pharmacother. 2001;35(11):1414-1425. View abstract. Freeman, M. P., Mischoulon, D., Tedeschini, E., Goodness, T., Cohen, L. S., Fava, M., and Papakostas, G. I. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J.Clin.Psychiatry 2010;71(6):682-688. View abstract. Frezza M and Terpin M. The use of S-adenosyl-L-methionine in the treatment of cholestatic disorders: a meta-analysis of clinical trials. Drug Invest 1992;4(Suppl. 4):101-108. Frezza M, Cammareri G, Di Padova C, and et al. Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter clinical trial 1987;5 suppl 1:S27. Frezza M, Di Padova C, and Italian Study Group for SAMe. Multicenter placebo controlled clinical trial of intravenous and oral S-adenosyl-L-methionine (SAMe) in cholestatic patients with Frezza, G., Chiesa, Di Padova, C. Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine administration. Hepatology 1984;4(2):274-278. View abstract. Frezza, M., Tritapepe, R., Pozzato, G., Di Padova, C. Prevention of S-adenosylmethionine of estrogen-induced hepatobiliary toxicity in susceptible women. Am J Gastroenterol 1988;83(10):1098-1102. View abstract. Furujo, M., Kinoshita, M., Kubo, T. S-adenosylmethionine in methionine adenosyltransferase deficiency, a case report. Mol.Genet.Metab 2012;105(3):516-518. View abstract. Gaster B. S-adenosylmethionine (SAMe) for treatment of depression. Alternative Medicine Alert 1999;12:133-135. Gerards, M., Sluiter, W., van den Bosch, B. J., de Wit, L. E., Calis, C. M., Frentzen, M., Akbari, H., Schoonderwoerd, K., Scholte, H. R., Jongbloed, R. J., Hendrickx, A. T., de Coo, I. F., and Smeets, H. J. Defective complex I assembly due to C20orf7 mutations as a new cause of Leigh syndrome. J.Med.Genet. 2010;47(8):507-512. View abstract. Giulidori, P., Cortellaro, M., Moreo, G., and Stramentinoli, G. Pharmacokinetics S-adenosyl-L-methionine in healthy volunteers. Eur J Clin Pharmacol 1984;27(1):119-121. View abstract. Glick, N. Dramatic reduction in in Lesch-Nyhan disease following S-adenosylmethionine administration. J.Inherit.Metab Dis. 2006;29(5):687. View abstract. Hanje, A. J., Fortune, B., Song, M., Hill, D., and McClain, C. The use of selected nutrition supplements and complementary and alternative medicine in liver disease. Nutr.Clin.Pract. 2006;21(3):255-272. View abstract. Hardy, M. L., Coulter, I., Morton, S. C., Favreau, J., Venuturupalli, S., Chiappelli, F., Rossi, F., Orshansky, G., Jungvig, L. K., Roth, E. A., Suttorp, M. J., and Shekelle, P. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evid.Rep.Technol.Assess.(Summ.) 2003;(64):1-3. View abstract. Ianniello A, Ostuni PA, Sfriso P, and et al. S-adenosyl-L-methionine in Sj\u00f6gren's syndrome and fibromyalgia. Curr Ther Res 1994;55(6):699-706. Jorge, A. D. Accion terapeutica de la SAMe en hepatitis aguda [Therapeutic action S-adenosyl-L-methionine in acute hepatitis]. Prensa Med Argent 1985;72(11):373-379. Jorm, A. F., Allen, N. B., O'Donnell, C. P., Parslow, R. A., Purcell, R., and Morgan, A. J. Effectiveness of complementary and self-help treatments for depression in children and adolescents. Med J Aust 10-2-2006;185(7):368-372. View abstract. Kaye, G. L., Blake, J. C., and Burroughs, A. K. Metabolism of exogenous S-adenosyl-L-methionine in patients with liver disease. Drugs 1990;40 Suppl 3:124-128. View abstract. Kharbanda, K. K. Methionine metabolic pathway in alcoholic liver injury. Curr.Opin.Clin.Nutr.Metab Care 2013;16(1):89-95. View abstract. Kharbanda, K. K., Bardag-Gorce, F., Barve, S., Molina, P. E., and Osna, N. A. Impact of altered methylation in cytokine signaling and proteasome function in alcohol and viral-mediated diseases. Alcohol Clin.Exp.Res. 2013;37(1):1-7. View abstract. Konig, H. and Saal, J. [Quantitatively evaluated magnetic resonance tomography as a therapeutic follow-up of the nonsteroidal antirheumatic ademetionin: a pilot study in patients with gonarthrosis]. Rofo 1990;152(2):214-219. View abstract. Kufferle, B. and Grunberger, J. Early clinical double-blind study with S-adenosyl-L-methionine: a new potential antidepressant. Adv.Biochem.Psychopharmacol. 1982;32:175-180. View abstract. Labo, G. and Gasbarrini, G. B. [Therapeutic action of S-adenosylmethionine in some chronic hepatopathies]. Minerva Med 5-2-1975;66(33):1563-1570. View abstract. Lafuenti, G., Plotti, G., Nicolanti, G., and obstetrical C. E., Mischoulon, D., and Papakostas, I. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. Eur.Psychiatry 2012;27(7):518-521. View abstract. Li, N., Zhang, H. H., Wang, S. H., Zhu, W. M., Ren, J. A., and Li, J. S. S-adenosylmethionine in treatment of cholestasis after total parenteral nutrition: laboratory investigation and clinical application. Hepatobiliary.Pancreat.Dis.Int. 2002;1(1):96-100. View abstract. Lo Russo, A., Monaco, M., Pani, A., and et al. Efficacy of s-adenosyl-l-methionine in relieving psychologic distress associated with detoxification in opiate users. Curr Ther Res 1994;55(8):905-913. Lu, S. C. and Mato, J. M. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 2012;92(4):1515-1542. View abstract. Mantero, M., Pastorino, A. study in syndromes]. 11-17-1975;66(78):4098-4101. View abstract. Manzillo G, Piccinino F, Surrenti C, and et al. Multicentre double-blind placebo-controlled study of intravenous and oral S-adenosyl-L-methionine (SAMe) in cholestatic patients with liver disease. Drug Invest 1992;4 (Suppl. 4):90-100. Marchesini G, Bugianesi E, Bianchi G, and et al. Effect of S-adenosyl-L-methionine administration on plasma levels of sulphur-containing amino acids in patients with liver cirrhosis. Clinical Nutrition 1992;11:303-308. Marcolongo R, Giordano N, and Colombo B. Double-blind multicentre study of the activity of S-adenosyl-L-methionine in hip and knee osteoarthritis. Curr Ther Res 1985;37(1):82-94. Mascio G, Guida Balestra V. Double-blind controlled clinical trial of SAMe administered orally in chronic liver diseases. Curr Ther Res 1983;33(6):1004-1013. Miccoli, L., Porro, V., and Bertolino, A. Comparison between the antidepressant activity and of S- adenosylmethionine (SAMe) and that of some tricyclic drugs. Bottiglieri, T., and Papakostas, G. I. Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder. J.Clin.Psychiatry 2012;73(6):843-848. View abstract. Monaco, P. and Quattrocchi, F. [Study of the antidepressive effects of and Caruso, I. Double-blind study of S-adenosyl-methionine versus in hip knee arthrosis. Clin Rheumatol . View abstract. Nierenberg, A. C., Brennan, B. P., Shelton, R. C., Perlis, R., and Iosifescu, D. V. Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development. Aust.N.Z.J.Psychiatry 2013;47(1):26-42. View abstract. Osman, E., Owen, J. S., and Burroughs, A. K. Review article: S-adenosyl-L-methionine--a new therapeutic agent in liver disease? 1993;7(1):21-28. View abstract. G. J. E., and Fava, M. S-adenosyl-methionine in depression: a comprehensive review of the literature. Curr.Psychiatry Rep. 2003;5(6):460-466. View abstract. Papakostas, G. I., Cassiello, C. F., and Iovieno, N. Folates and S-adenosylmethionine for major depressive disorder. Can.J.Psychiatry 2012;57(7):406-413. View abstract. Pecoraro, V., Bruno, M., Mal Infett Parassit 1979;31(6):390-394. Plasencia AM, Garcia MM, Torres AC, and et al. Total parenteral nutrition plus S-adenosylmethionine in a case of intrahepatic cholestasis. Drug Investigation 1991;3(5):333-335. Porter, N. S., Jason, L. A., Boulton, A., Bothne, N., and Coleman, B. Alternative medical interventions used in the treatment and management of myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia. J.Altern.Complement Med. 2010;16(3):235-249. View abstract. Potkin, S. G., Bell, K., Plon, L., and Bunney, W. E., Jr. Rapid antidepressant response with SAMe. A double-blind study. Alabama Journal of Medical Sciences 1988;25(3):313-316. View abstract. Qin, B., Guo, S., Zhao, Y., Zou, S., Zhang, Q., Wang, Z., Zeng, W., and Zhang, D. A trial of ademetionine in the treatment of intrahepatic biliary stasis viral hepatitis. Zhonghua Gan Zang.Bing.Za Zhi 2000;8(3):158-160. View abstract. Ribalta, J., Reyes, H., Gonzalez, M. C., Iglesias, J., Arrese, M., Poniachik, J., Molina, C., and Segovia, N. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo- 1991;13(6):1084-1089. View abstract. Roncaglia N, Locatelli A, Bellini P, and et al. A randomized controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. Am J Obstet Gynecol 2000;182(1 pt 2):S167. Rosenbaum, J. F., Fava, M., Falk, W. E., Pollack, M. H., Cohen, L. S., Cohen, B. M., and Zubenko, G. S. An open-label pilot study of oral S-adenosylmethionine in major depression. An interim report. Ala J Med Sci 1988;25(3):301-306. View abstract. Rutjes, A. W., Nuesch, E., Reichenbach, S., and Juni, P. S-Adenosylmethionine for osteoarthritis of the knee or hip. Cochrane.Database.Syst.Rev. 2009;(4):CD007321. View abstract. Salvadorini F, Galeone F, Saba P, and et al. Evaluation of S-adenosyl-L-methionine (SAMe) effectiveness on depression. Current Therapeutic Research 1980;27(6 section 2):908-917. Santini, D., Vincenzi, B., A., L., Marcucci, Montesarchio, G. (AdoMet) for treatment chemotherapy-induced liver Anticancer View abstract. Sarris, J. Clinical depression: an evidence-based integrative complementary medicine treatment model. Altern.Ther.Health Med. View Scaggion, G., Baldan, L., Cenci, R., nomifensine L., Thomas, J., and Bazzan, A. J. SAMe use in children and adolescents. Eur.Child Adolesc.Psychiatry 2004;13(5):332-334. View abstract. Shippy, R. A., Mendez, D., K., Cergnul, I., and Karpiak, S. E. S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS. BMC.Psychiatry 11-11-2004;4:38. View abstract. Silveri, M. M., Parow, A. M., Villafuerte, R. A., Damico, K. E., Goren, J., Stoll, A. L., Cohen, B. M., and Renshaw, P. F. S-adenosyl-L-methionine: effects on brain bioenergetic status and transverse relaxation time in healthy subjects. Biol.Psychiatry 10-15-2003;54(8):833-839. View abstract. Stramentinoli, G. and Catto, E. Pharmacokinetic studies of SAMe in several animal species. Pharmacol Res Com 1976;8:211-218. Stramentinoli, G. Pharmacologic aspects of S-adenosylmethionine. and Med 11-20-1987;83(5A):35-42. View abstract. Trespi A, Vigoni R, Matti C, and et al. TUDCA, UDCA and Ademetionine (Ade) in the treatment of [abstract]. J Hepatol 1997;26:128. Vendemiale, Trizio, T., Grazie, C., Di Padova, C., Salerno, M. T., Carrieri, V., and Albano, O. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol 1989;24(4):407-415. View abstract. Williams, A. L., Girard, C., Jui, D., Sabina, A., and Katz, D. L. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clin Invest Med 2005;28(3):132-139. View abstract. Yang, J., He, Y., Du, Y. X., Tang, L. L., Wang, G. J., and Fawcett, J. P. Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous tosylate disulfate salt: a Clin.Ther. 2009;31(2):311-320. View abstract. Yousef, I. M., Barnwell, S. G., Tuchweber, B., Weber, A., and Roy, C. C. Effect of complete sulfation of bile acids on bile formation in rats. Hepatology 1987;7(3):535-542. View abstract. Aggarwal R, Sentz J, Miller MA. Role of zinc administration in prevention of childhood diarrhea and respiratory illnesses: a meta-analysis. Pediatrics 2007;119:1120-30. View abstract. Almasio P, Bortolini M, Pagliaro L, Coltorti M. Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis. Drugs 1990;40:111-23. View abstract. Alpert JE, Papakostas G, Mischoulon D, et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol 2004;24(6):661-64. View abstract. American Dental Association. \"ADA Statement on FDA Toothpaste Warning Labels\" https://www.ada.org/prof/prac/issues/statements/fluoride.html (Accessed 18 November 2002). Ancarani E, Biondi B, Bolletta A, et al. Major depression complicating hemodialysis in patients with chronic renal failure: a multicenter, double-blind, controlled clinical trial of S-adenosyl-L-methionine versus Curr Ther Res 1993;54(6):680-6. Arnold Anderer al. Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry. Eur Neuropsychopharmacol 2005;15:533-43. View abstract. Bell KM, Plon L, Bunney WE Jr, Potkin SG. S-adenosylmethionine treatment of depression: a controlled clinical trial. Am J Psychiatry 1988;145:1110-4. View abstract. Bell KM, Potkin SG, Carreon D, Plon L. S-adenosylmethionine blood levels in with drug treatment. Acta Neurol Scand Suppl 1994;154:15-8. View abstract. Berger R, Nowak H. A new medical approach to the treatment of osteoarthritis. Report of an open phase IV study with ademetionine (Gumbaral). Am J Med 1987;83:84-8. View abstract. Berlanga C, Ortega-Soto HA, Ontiveros M, Senties H. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res 1992;44:257-62. View abstract. Binder T., Salaj P., Zima T., Vitek L. [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekol T., Vitek L. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. J Perinat Med 2006;34(5):383-391. View abstract. Bombardieri G, Milani A, Bernardi L, et al. Effects of S-adenosyl-L-methionine (SAMe) in the treatment of Gilbert's syndrome. Curr Ther Res 1985;37(3):580-585. Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994;48:137-52. View abstract. Bottiglieri T. S-Adenosyl-L-methionine (SAMe): from the bench to the bedside--molecular basis of a pleiotrophic molecule. Am J Clin Nutr 2002;76:1151S-7S. View abstract. Bradley JD, Flusser D, Katz BP, et al. A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis. J Rheumatol 1994;21:905-11. View abstract. Bressa GM. S-adenosyl-l-methionine P., Gentilini, P. [Ursodeoxycholic hemisuccinate in the treatment of chronic active hepatitis. A controlled clinico-therapeutic study]. Minerva Med 1992;83(9):537-540. View abstract. Cacciatore L, Varriale A, Cozzolino G, et al. S-adenosylmethionine (SAMe) in the treatment of pruritus in chronic liver disease. Acta Therapeutica 1989;15:363-371. Carney MW, Chary TK, Bottiglieri T, Reynolds EH. The switch mechanism and the bipolar/unipolar dichotomy. Br J Psychiatry 1989;154:48-51. View abstract. Carrieri PB, Indaco A, Gentile S, et al. S-adenosylmethionine treatment depressioin in patients with Parkinson's disease: study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease. Am J Med 1987;83:66-71. View abstract. Castagna A, Le Grazie C, Accordini A, et al. Cerebrospinal fluid S-adenosylmethionine (SAMe) and glutathione concentrations in HIV infection: effect of parenteral treatment with SAMe. Neurol 1995;45:1678-83. View abstract. Ceccato S, Cucinotta D, Carapezzi C, et al. [Double-blind clinical study of the therapeutic effect of SAMe and Ibuprofen in degenerative osteoarticular pathology]. G Clin Med rationale for its use in liver disease. Drugs 1990;40:98-110. View abstract. Cowley G, Underwood A. Newsweek. July 5, 1999; pp. 46-50. Czap A. Beware the son of SAMe. Altern Med Rev 1999;4:73. View abstract. De Berardis D, Marini Serroni Martinotti G, Di Giannantonio M. S-Adenosyl-L-Methionine augmentation in patients with stage II treatment-resistant major depressive disorder: an open label, fixed dose, single-blind study. ScientificWorldJournal 2013;2013:204649. View abstract. De Silva V, El-Metwally A, Ernst E, et al. Evidence for the efficacy of complementary and alternative medicines in the management of osteoarthritis: a systematic review. Rheumatology (Oxford) 2011;50(5):911-920. View abstract. Delle Chiaie R, Pancheri P, and tolerability of oral and intramuscular S-adenosyl-Lmethionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in multicenter studies. Am J Clin Biswas M. Evaluation of antiepileptic activity of S-adenosylmethionine and its role in memory impairment in pentylenetetrazole-induced kindling model in rats. Epilepsy Behav 2016;61:153-7. View abstract. Di Benedetto P, Iona LG, Zidarich V. Clinical evaluation of S-adenosyl-L-methionine versus transcutaneous electrical nerve stimulation in primary fibromyalgia. Curr Ther Res 1993;53(2):222-229. di Padova C. S-adenosylmethionine in the treatment of osteoarthritis. Review of the clinical studies. Am J Med 1987;83:60-5. View abstract. Diaz BA, Dominguez HR, Uribe AF. Parenteral S-adenosylmethionine compared to placebos in the treatment of alcoholic liver diseases. An Med Interna 1996;13:9-15. View abstract. Dolcetta D, Parmigiani G, Nyhan WL, Hladnik U. Quantitative evaluation of the clinical effects of S-adenosylmethionine on mood and behavior in Lesch-Nyhan patients. Nucleosides Nucleotides Acids Pucar I. A double-blind trial of Shyu I., Alpert J. E., Papakostas G. I. SAMe and sexual functioning. Eur Psychiatry 2012;27(6):451-454. View abstract. Fava M, Giannelli A, Rapisarda V, et al. Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. Psychiatry Res 1995;56:295-7. View abstract. FDA. List of orphan designations and approvals. Office of Orphan Products Development. Available at: www.fda.gov/orphan/designat/list.htm. Feld J. J., Modi A. A., El-Diwany Thomas E., Ahlenstiel G., Titerence R., Koh C., Cherepanov V., Heller T., Ghany M. G., Park Y., Hoofnagle J. H., Liang, T. J. S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Gastroenterology Bernsmeier F. H., Heim M. H. S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse. PLoS One 2010;5(11):e15492. View abstract. Floreani A., A., Grella P. V. S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. J Obstet Gynecol Reprod Biol 1996;67(2):109-113. View et al. S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepatogastroenterology 1990;37:122-5. View abstract. Frezza M, Surrenti C, Manzillo G, et al. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A [A meta-analysis of therapeutic trials with ademetionine in the treatment of intrahepatic cholestasis]. Ann Ital Benfield P. S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989;38:389-416. View abstract. Galizia I, Oldani L, Macritchie K, et al. S-adenosyl methionine (SAMe) for depression in adults. Cochrane Database Syst Rev. 2016;10:CD011286. View abstract. Gentile S., Persico M., Orlando C., Le Grazie C., Di Padova C., Coltorti M. Effect of different doses of S-adenosyl-L-methionine (SAMe) on nicotinic acid-induced hyperbilirubinaemia in Gilbert's syndrome. Scand Clin 1988;48(6):525-529. View abstract. Glorioso S, Todesco S, Mazzi A, et al. Double-blind, multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis. Int J Clin Pharmacol Res 1985;5:39-49. View abstract. Goren JL, Stoll AL, Damico KE, et al. Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacotherapy 2004;24:1501-7. View abstract. Green T., Steingart L., Frisch A., Zarchi O., Weizman A., Gothelf D. The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 syndrome: a [S-Adenosylmethionine: plasma levels in hepatic cirrhosis and preliminary results of its clinical use in hepatology. Double-blind study]. interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry 1993;150:522. View abstract. Jacobsen S, Danneskiold-Samsoe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol 1991;20:294-302. View abstract. Janicak P. G., Lipinski J., Davis J. M., Altman E., Sharma R. P. Parenteral S-adenosyl-methionine (SAMe) in depression: literature review and preliminary data. Psychopharmacol Bull 1989;25(2):238-242. View abstract. Janicak PG, Lipinski J, Davis JM, et al. S-adenosylmethionine in depression. A literature review and preliminary report. Ala J Med Sci 1988;25:306-13. View abstract. Kadakia KC, Loprinzi CL, Atherton PJ, Fee-Schroeder KC, Sood A, Barton DL. Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes. Support Care Cancer. 2016;24(3):1061-9. View abstract. Kagan BL, Sultzer DL, placebo-controlled trial. Am J Psychiatry 1990;147:591-5. View abstract. Kim J, Lee EY, Koh EM, et al. Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, Clin Ther 2009;31(12):2860-2872. View abstract. Konig B. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis. Am J Med 1987;83:89-94. View abstract. Lafuenti G., Plotti G., Nicolanti G., Gaglione R., Tibollo F. G., Mancuso S. [Evaluation of the obstetrical risk in pregnant women with intrahepatic cholestasis treated with Recenti Prog Laudanno OM. Cytoprotective S-adenosylmethionine compared with that of misoprostol against ethanol-, aspirin-, and stress-induced gastric damage. Am J Med 1987;83(5A):43-7. View abstract. Lieber CS, Packer L. S-Adenosylmethionine: molecular, biological, and clinical aspects\u2014an introduction. Am J Clin Nutr 2002;76:1148S-50S.. View abstract. Lieber CS. S-Adenosyl-L-methionine: its role in the treatment of liver disorders. Am J Clin Nutr 2002;76:1183S-17S.. View abstract. Lipinski JF, Cohen BM, Frankenburg F, et al. Open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry 1984;141:448-50. View abstract. Loehrer FM, Angst CP, Haefeli WE, et al. Low whole-blood S-adenosylmethionine and correlation between 5-methyltetrahydrofolate and Arterioscler Thromb Vasc 1996;16:727-33. View abstract. Loehrer FM, Schwab R, Angst CP, et al. Influence of oral S-adenosylmethionine on plasma 5-methyltetrahydrofolate, S-adenosylhomocysteine, homocysteine View abstract. Loguercio C, Nardi G, Argenzio F, et al. Effect of S-adenosyl-L-methionine administration on red blood cell cysteine and glutathione levels in alcoholic patients with and without liver disease. Alcohol 1994;29:597-604. View abstract. Maccagno A, Di Giorgio EE, Caston OL, Sagasta CL. Double-blind controlled clinical trial of oral S-adenosylmethionine versus piroxicam in knee osteoarthritis. Am J Med 1987;83:72-7. View abstract. Manzillo G, Piccinino F, Surrenti C, et Multicentre double-blind study of intravenous and oral S-adenosyl-L-methionine (SAMe) in cholestatic patients with liver disease. Drug Invest 1992;4 (Suppl 4):90-100. Marchesini G, Bugianesi E, Bianchi G, et al. Effect of S-adenosyl-L-methionine administration on plasma levels of sulphur-containing amino acids in patients with liver cirrhosis. Clinical Nutrition 1992;11:303-308. Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, et al. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of liver injury. Am J Clin Nutr 2002;76:1177S-82S.. View abstract. Mato JM, Camara J, Fernandez de Paz J, et al. in alcoholic liver cirrhosis: a randomized, placebo-controlled, V., Virata M. C., Peerson J. M., Stabler S. P., French S. W., Gregory J. F. III, Albanese A., Bowlus C. L., Devaraj S., Panacek E. A., Richards J. R., Halsted C. H. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, M, Chiti D, Balestra V. Double-blind controlled clinical trial of SAMe administered orally in chronic liver diseases. Curr Ther Res 1983;33(6):1004-1013. Miglio F., Stefanini R., D'Ambro A., Gasbarrini G. [Double-blind studies of the therapeutic action of S-Adenosylmethionine (SAMe) in oral administration, in liver cirrhosis and other chronic hepatitides]. Minerva Med 1975;66(33):1595-1599. View abstract. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr 2002;76:1158S-61S.. View abstract. Morrison LD, Smith DD, Kish SJ. Brain s-adenosylmethionine levels are severely decreased in Alzheimer's disease. J Neurochem 1996;67(3):1328-31. View abstract. Muller-Fassbender H. Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in the treatment of osteoarthritis. Am J Med 1987;83:81-3. View abstract. Murphy BL, Babb SM, Ravichandran C, Cohen a double-blind, clinical G, Galzenati M, Balbi A. SAMe versus placebo: a double blind comparison in major depressive disorders. Advances in Biochemical Psychopharmacology 1982;32:151-6. View abstract. Musso P., Cerutti, A. [The use of silymarin and SAMe in the treatment of acute infective hepatitis in childhood]. Minerva Pediatr 1980;32(17):1057-1067. View al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment double-blind crossover S-adenosyl methionine (SAMe) augmentation in major depressive disorder. (Editorial). Am J Psychiatry 2010;167:889-91. View abstract. Nicastri P. L., Diaferia A., Tartagni M., P., Fanelli A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. Br J Obstet Gynaecol 1998;105(11):1205-1207. View A, Napolitano al. S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy Regimens. Chemotherapy 2021;66(5-6):161-168. View abstract. R. of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Int J Neuropsychopharmacol 2002;5(4):287-94. View abstract. Papakostas GI, Mischoulon D, S-adenosyl augmentation of serotonin reuptake inhibitors with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 2010;167:942-8. View abstract. [S-adenosylmethionine P, Ingrosso D, et al. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin. J Nephrol 1999;12:230-40. View abstract. Plotkin L. L., Bespalov A. M., Smirnov D. M., Timchenko N. N., Shapovalova IuS, Konradi A. B. [Clinical signs of endothelial disorders in patients with severe sepsis]. Reanimatol 2012;(2):48-51. abstract. Podymova SD, Nadinskaia M. [Clinical trial of heptral in patients with chronic diffuse liver disease with intrahepatic cholestasis syndrome]. Klin M, Parrini L, et al. [Pharmacological and clinical aspects of S-adenosylmethionine (SAMe) in primary degenerative arthropathy (osteoarthrosis)]. Minerva Med 1975;66(83):4443-59. abstract. PremesisRx. Pharmacist's Letter / Prescriber's Letter 1999:15(12);151206. Purohit V, Russo D. Role of S-adenosyl-L-methionine in the treatment of alcoholic liver disease: introduction and summary of the symposium. Alcohol 2002;27:151-4. View abstract. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Syst Rev 2006;(2):CD002235. [RETRACTED]. View abstract. Ravindran AV, Balneaves LG, Faulkner G, et al.; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments. Can J Psychiatry 2016;61(9):576-87. View abstract. Ravindran AV, Lam RW, Filteau MJ, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. J Affect Disord 2009;117 Suppl 1:S54-64. View Cameroni I., Pezzullo J. C., Ghidini A. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis. BJOG 2004;111(1):17-21. View abstract. Rosenbaum J. F., Fava M., Falk W. E., Pollack M. H., Cohen L. S., Cohen B. M., Zubenko G. S. An open-label pilot study of oral S-adenosyl-L-methionine in major depression: interim results. Psychopharmacol Bull 1988;24(1):189-194. View abstract. Rosenbaum JF, Fava M, Falk WE, et al. The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand 1990;81:432-6. C. Electrophysiological neuroimaging of the central effects of S-adenosyl-L-methionine by mapping of electroencephalograms and event-related potentials and low-resolution brain electromagnetic tomography. 2002;76:1162S-71S.. View al. Double-blind, View WO, Antun F, Hanna et al. S-adenosyl-L-methionine (SAM) in adults with ADHD, RS: preliminary results from an open trial. Psychopharmacol Bull 1990;26:249-53.. View abstract. Shilov V. V., Shikalova I. A., Vasil'ev S. A., Batotsyrenov B. V., Andrianov Alu. [Correction of metabolic disorders during treatment of alcohol-induced liver injuries in patients with acute alcoholic intoxication]. Klin Med (Mosk) 2013;91(2):45-48. View abstract. Begleiter AF, et al. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology 2002;58:130-3. View abstract. Soeken KL, Lee WL, Bausell RB, et al. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. J Fam Pract 2002;51:425-30. View abstract. Sood A, Prasad K, Croghan et al. S-adenosyl-L-methionine (SAMe) for smoking abstinence: a randomized clinical trial. J Altern Complement Med 2012;18(9):854-9. View abstract. Stramentinoli G, Gualano M, Ther 1979;209:323-6. View abstract. Strous Adler S., Ratner Y., Maayan R., Kotler M., Lachman H., Weizman, A. Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia. Eur Neuropsychopharmacol 2009;19(1):14-22. ZL, Jia Beneficial effects of S-adenosyl-L-methionine on post-hepatectomy residual liver function: a prospective, randomized, controlled clinical trial. Hepatogastroenterology 2013;60(125):1136-41. View abstract. Sun Q. F., Ding J. G., Wang X. F., Fu R. Q., Yang J. X., Hong L., Xu X. J., Wang J. R., Wu J. G., Xu D. Z. Efficacy and safety of intravenous stronger neo-minophagen C and S-adenosyl-L-methionine in treatment of pregnant woman with chronic hepatitis B: a pilot study. Med Sci Monit 2010;16(8):R9-14. View abstract. Tan SV, Guiloff RJ. Hypothesis pathogenesis of vacuolar peripheral neuropathy in AIDS. Neurol Psychiatry 1998;65:23-8. View abstract. Tavoni A, Vitali C, Bombardieri S, Pasero G. Evaluation of S-adenosylmethionine in primary fibromyalgia. A double-blind crossover study. Am J Med 1987;83:107-10. View abstract. Tavoni A., Jeracitano G., Cirigliano G. Evaluation double-blind study. Clin Exp View abstract. Thomas C. S., Bottiglieri T., Edeh J., Carney M. W., Reynolds E. H., Toone B. K. The influence of S-adenosylmethionine (SAM) on prolactin in depressed patients. Int Clin Psychopharmacol 1987;2(2):97-102. View abstract. Vahora SA, Malek-Ahmasi P. the treatment of depression. Neurosci Biobehav Rev 1988;12:139-41. View abstract. Vetter G. Double-blind comparative clinical trial with S-adenosylmethionine and indomethacin in the treatment of osteoarthritis. Am J Med 1987;83:78-80. View abstract. Volkmann H, Norregaard J, Jacobsen S, et al. Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia. Scand J Rheumatol 1997;26:206-11. View abstract. Werneke U, Turner T, Priebe S. Complementary medicines in psychiatry: review of effectiveness and safety. Br J Psychiatry 2006;188:109-21. View abstract. Work Group for Major Depressive Disorder. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. American Psychiatric Association, May 2010 (Published October 2010). Available at: https://www.psych.org/guidelines/mdd2010. Zhu SS, Dong Y, Gan Y, et al. [Efficacy and safety of ademetionine for treatment of drug-induced liver disease in children]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2010;24(2):136-138. View abstract. Select a condition to view a list of vitamins You Might Also Like CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you. This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version. \u00a9 Therapeutic Research Faculty 2020. "}